BRAF and neoplasm: The Encorafenib, binimetinib and cetuximab in subjects with previously untreated BRAF-mutant CRC (ANCHOR-CRC) (NCT03693170) study released results in August 2022: the investigator-assessment confirmed that ORR based on local tumor assessments was 47.8% (95% CI 37.3–58.5%), and the median PFS per local review was 5.8 months (95% CI 4.6–6.4 months) [132].